Compare the purchase with the work needed to sustain it.

NHS England's procurement resources explain national framework arrangements, while its supply guidance describes local and escalation responsibilities (NHS England, n.d.; NHS England, n.d.). The proposed task starts by establishing which arrangements actually apply. An option outside an authorised route is not made viable by an attractive model. Identify the decision the team can make, such as an ordering or review process within existing permissions. Keep contractual obligations and professional supply-management responsibilities visible so the analysis supports the accountable buyer rather than inventing authority for the software.

The comparison might examine two permitted ordering approaches for a defined product group, using authorised aggregate information. Record demand assumptions, lead-time observations, stock limits and the reporting period. Show a range where the input varies. A scenario is a way to explore consequences; it is not a forecast that supply will behave as modelled. The team should be able to change an assumption and see which conclusion changes, including whether the apparent advantage disappears under plausible conditions.

A first PHARMORIS evaluation could compare the procurement team's existing review pack with a prepared options brief using the same approved inputs. Independent procurement and pharmacy reviewers would assess completeness, traceability and the handling of constraints. The initial scope would not place orders, select suppliers, alter stock levels or issue clinical substitutions. It would test whether a bounded preparation task becomes more useful. Any later operational use would require a separate decision about integration, assurance and responsibility.

Stop if an output invents availability, assumes framework eligibility or recommends an action outside the agreed decision boundary. Pause if demand and lead-time information cannot support the intended scenario. Agree a maximum checking burden before the study begins. A finding that better local data is needed can be commercially useful: it prevents investment in a tool whose attractive answers depend on unavailable inputs. Resilience is strengthened by understanding uncertainty, not by producing a more confident picture of it.

A trust procurement pharmacist, purchasing lead and finance representative can begin with a recurring review and the constraints that make it difficult. We can discuss permitted inputs, the current comparator and an outcome that would justify further work. The potential incentive is a clearer decision with less avoidable preparation and rework. PHARMORIS remains under development; the proposed evaluation would establish whether that value exists in the selected task before any broader proposition about supply performance is made.